Citi raised the firm’s price target on Alcon (ALC) to CHF 101 from CHF 99 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon’s Stock Boosted by FDA Approval of Innovative Dry Eye Drug TRYPTYR
- Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target
- Alcon Secures FDA Approval for TRYPTYR to Treat Dry Eye Disease
- Alcon’s Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease
- Alcon upgraded to Buy from Hold at Kepler Cheuvreux